Listed Companies To Benefit First From Biomedical Revitalization Plan
This article was originally published in PharmAsia News
Executive Summary
Analysts predict the "Biomedical Revitalization Plan" to be released later this month, which will focus on vaccines, protein-based drugs, and monoclonal antibodies, will likely benefit listed biotech drug manufacturers first